Where muscle
becomes medicinefor muscle wasting
First-in-class oral compounds that switch on muscle's metabolic machinery without the signaling liabilities that have blocked conventional β₂-drugs for nearly six decades.
Muscle is at the centre of health.
Muscle does far more than move us. It shapes metabolic, skeletal, immune and cognitive health, and our capacity to recover.
higher risk of death from any cause for every 5 kg lower grip strength. It predicted death better than systolic blood pressure.
Muscle is being lost. And power goes first.
Weight loss on GLP-1 therapy includes muscle loss.
of the weight lost on semaglutide is lean mass
| Lean mass (%) | Fat mass (%) | |
|---|---|---|
| Semaglutide 2.4 mg (STEP 1) | 40 | 60 |
| Tirzepatide (SURMOUNT-1) | 25 | 75 |
Sarcopenia is common, and it raises the odds of death.
of adults aged 60 and over have sarcopenia
| Pooled odds ratio vs. people without sarcopenia | |
|---|---|
| Mortality | 3.6× |
| Functional decline | 3.0× |
| Falls | 1.9× |
| Fractures | 1.7× |
Power fails first, and fastest.
of leg power lost each year in healthy adults aged 65–89, from a decline that starts around 40
- 01Power declines
- 02Strength and mobility fall
- 03Falls, frailty, dependence
- 04Morbidity and mortality rise
| Annual decline | |
|---|---|
| Muscle mass | 1.0% |
| Muscle strength | 1.5% |
| Muscle power | 3.5% |
Low power carries 5.9–6.9× the mortality risk; low strength 1.6–1.7× (CLINIMEX, n = 3,889).
Protecting muscle power helps protect life.
Eight pathways. We keep two.
Classical β₂ agonists switch on every pathway, including the ones that strain the heart and wear the receptor out. The Atrogi class keeps glucose uptake and GRK2 and leaves the rest near zero.
Fuels muscle. Builds muscle.
Like exercise, one GRK2-biased signal does both. It drives glucose into muscle without insulin, and it preserves and builds muscle mass in preclinical models.